Seamless Therapeutics

The company develops a gene-editing platform based on programmable recombinase technology to treat severe genetic diseases. Its technology enables large, precise DNA deletions or insertions at specific genomic sites without introducing additional mutations. The firm is building a pipeline of disease-modifying product candidates, including research collaborations for indications such as hearing loss.